Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142259 |
| CAS No | NA |
| Mol.F. | C13H19N3O2 |
| Mol.Wt. | 249.31 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142260 |
| CAS No | NA |
| Mol.F. | C14H17Br2N3O2 |
| Mol.Wt. | 419.12 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142261 |
| CAS No | NA |
| Mol.F. | C13H18BrN3O2 |
| Mol.Wt. | 328.21 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142262 |
| CAS No | NA |
| Mol.F. | C26H36Br2N4O4 |
| Mol.Wt. | 628.41 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142263 |
| CAS No | NA |
| Mol.F. | C26H36Br2N4O4 |
| Mol.Wt. | 628.41 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142264 |
| CAS No | NA |
| Mol.F. | C16H21Br2N3O4 |
| Mol.Wt. | 479.17 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142265 |
| CAS No | NA |
| Mol.F. | C16H21Br2N3O4 |
| Mol.Wt. | 479.17 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142266 |
| CAS No | NA |
| Mol.F. | C15H19Br2N3O4 |
| Mol.Wt. | 465.14 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142267 |
| CAS No | NA |
| Mol.F. | C15H19Br2N3O4 |
| Mol.Wt. | 465.14 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142268 |
| CAS No | NA |
| Mol.F. | C16H21Br2N3O4 |
| Mol.Wt. | 479.17 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142269 |
| CAS No | NA |
| Mol.F. | C11H14N2O2 |
| Mol.Wt. | 206 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142270 |
| CAS No | NA |
| Mol.F. | C7H7N5O3 |
| Mol.Wt. | 209.17 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142271 |
| CAS No | NA |
| Mol.F. | C23H26N2O4 |
| Mol.Wt. | 394.47 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142272 |
| CAS No | NA |
| Mol.F. | C23H25IN2O4 |
| Mol.Wt. | 520.37 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142273 |
| CAS No | NA |
| Mol.F. | C24H26I2N2O5 |
| Mol.Wt. | 676.29 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142274 |
| CAS No | NA |
| Mol.F. | C4H9ClN2O |
| Mol.Wt. | 136.58 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |